Učitavanje...
An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany
BACKGROUND: This study aimed to evaluate cost-utility of baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatmen...
Spremljeno u:
| Izdano u: | BMC Cardiovasc Disord |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6085633/ https://ncbi.nlm.nih.gov/pubmed/30092774 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-018-0898-x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|